▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #30 by analyst upside · 2026-11-13
NRSN
NeuroSense Therapeutics Ltd.
Healthcare · Market Cap $3M · P/E 0x
ANALYST PRICE TARGET
+5113.1%
implied upside to consensus target
Current Price $1.76
Consensus Target $91.75
Bull Target $180.0
Bear Target $3.5
Analysts Covering 2
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
1
Hold
1
Sell
0
52-Week Low $1.1
52-Week High $25.4
YTD Return -88.7%
FUNDAMENTALS
Market Cap $3M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-47.10
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.1
52-Week High $25.4
Current Price $1.76
Bear Target $3.5
Bull Target $180.0
● Now $1.76 ● Target $91.75
TRADING DATA
Avg Volume 32K
YTD Return -88.7%
Analyst Count 2
Consensus Buy
Upside to Target +5113.1%
Last Updated 2026-11-13

ANALYST SUMMARY

NeuroSense Therapeutics Ltd. (NRSN) is currently trading at $1.76 with a Wall Street consensus price target of $91.75, implying potential upside of 5113.1% over the next 12 months. 2 analysts currently cover NRSN, with a consensus rating of Buy - 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $180.0, while the most cautious has a target of $3.5.

NRSN operates in the Healthcare sector with a market capitalisation of $3M. The stock is down 88.7% year-to-date and is currently trading near the lower end of its 52-week range of $1.1 – $25.4.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for NRSN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. ↓ Downgrade
Buy → Neutral 2026-11-02 31% win rate (48 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-09-28 31% win rate (48 calls)
HC Wainwright & Co. ● Initiated
Buy 2026-09-03 31% win rate (48 calls)
D. Boral Capital - Reiterated
Buy → Buy 2026-04-08 32% win rate (25 calls)
D. Boral Capital - Reiterated
Buy → Buy 2026-03-25 32% win rate (25 calls)
D. Boral Capital - Reiterated
Buy → Buy 2026-03-17 32% win rate (25 calls)
Roth Capital ● Initiated
Buy 2026-03-10 Building track record
D. Boral Capital - Reiterated
Buy → Buy 2026-03-09 32% win rate (25 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
15
out of 100
Coverage depth
8/30
Consensus clarity
0/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →